Histofy
Histofy is a UK-based company specializing in transparent AI solutions for computational pathology, focusing on tissue-based diagnostics and prognostics. Originating as a spin-out from the University of Warwick's Tissue Image Analytics Centre, Histofy develops advanced AI algorithms that integrate seamlessly into existing pathology workflows to enhance accuracy and efficiency in reporting. Their products support clinical care and pharmaceutical research, enabling faster, more accurate decisions in cancer diagnostics and toxicologic assessment. The company leverages over 20 years of research and 250 publications, positioning itself as a leader in AI-driven pathology solutions with a strong emphasis on patient-focused, transparent, and adaptable technology.
Histofy
Histofy is a UK-based company specializing in transparent AI solutions for computational pathology, focusing on tissue-based diagnostics and prognostics. Originating as a spin-out from the University of Warwick's Tissue Image Analytics Centre, Histofy develops advanced AI algorithms that integrate seamlessly into existing pathology workflows to enhance accuracy and efficiency in reporting. Their products support clinical care and pharmaceutical research, enabling faster, more accurate decisions in cancer diagnostics and toxicologic assessment. The company leverages over 20 years of research and 250 publications, positioning itself as a leader in AI-driven pathology solutions with a strong emphasis on patient-focused, transparent, and adaptable technology.
TL;DR
Founded: 2021 (University of Warwick spin-out)
Headquarters / Base: United Kingdom
Focus: Transparent AI for computational pathology (clinical diagnostics, prognostics, biopsy screening, pharma image analysis)
Flagship offerings: MitPro® (mitosis profiling); large bowel/colon biopsy screening AI
Notable investors / funding signals: Lumiares investment (Jul 2024); Source BioScience strategic investment (May 2025); NIHR grant (~£500K, Mar 2023)
≈11 employees
Company Overview
Problem Domain
Computational pathology: tissue image analytics for diagnostics, prognostics, biopsy screening and pharmaceutical research
Founded
2021
Industry
DeepTech
Tech Stack
Funding Track Record
£500K
NIHR-funded project to develop algorithms for endoscopic colon biopsy screening
Lumiares announced an investment alongside clinician co-investors
Strategic investment and partnership to explore integration and deployment of Histofy’s AI in pathology laboratories
Investor Signal
“Has received grant funding (NIHR) and strategic/VC investments (Lumiares; Source BioScience strategic investor)”